Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone? by O'Brien, Daniel P et al.
OPINIONMoxifloxacin for Buruli ulcer/HIV coinfected
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tuberculosisBuruli ulcer is a necrotizing infection of skin and soft
tissue caused by Mycobacterium ulcerans that results in
significant morbidity and often long-term disability. It is
endemic in West and Central Africa affecting
regions similarly burdened by a high prevalence of
HIV. According to the Me´decins Sans Frontie`res
programme in Akonolinga, Cameroon, the prevalence
of HIV is approximately three to six times higher in
Buruli ulcer-treated patients compared to the regional
estimated HIV prevalence [1]. Similarly in Benin, patients
with Buruli ulcer were eight times more likely to have
HIV infection than those without Buruli ulcer [2].
HIV also affects the clinical presentation of Buruli ulcer
disease with an increased incidence of multiple, larger,
and ulcerated lesions [1,3]. Patients often present with
severe immunosuppression, with 26% of patients in
Akonolinga presenting with CD4þ cell counts less than
200 cells/ml, and in urgent need of antiretroviral therapy
[1].
The treatment of Buruli ulcer has undergone a dramatic
evolution in recent years, with antibiotics being shown to
be highly effective in treating disease and preventing
recurrences [4–7]. Combination antibiotics for 8 weeks
are now the recommended first-line treatment [8].ippincott Williams & Wilkins. Unaut
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0269-9370 Q 2013 Wolters Kluwer HeaRifampicin and streptomycin is the most widely used
combination, but increased toxicity [9], difficulties in
administration, drug shortages [10], and impediments
to decentralization of treatment that result from the use
of injectable streptomycin have led to an increasing use
of the oral combination of rifampicin and clarithromycin.
This has been shown in mouse models [11] and obser-
vational cohorts to be effective [6].
Little is known about the optimal timing of antiretroviral
therapy (ART) in HIV patients treated for Buruli ulcer,
nor the optimal ART regimens to use. Nevertheless,
recent WHO recommendations have followed those of
tuberculosis/HIV (TB/HIV) and recommended ART be
commenced in all HIV patients early during the course of
Buruli ulcer antibiotic treatment [8]. As nevirapine and
boosted protease inhibitors are not recommended for
use in patients on rifampicin [12], many patients will be
taking efavirenz (EFV) in the ART regimen. However,
EFV can reduce clarithromycin levels by up to 39% [13],
which likely further compounds the known significant
reduction of clarithromycin levels by rifampicin [14].
Although the clinical consequences of these interactions
are unknown, it could potentially lead to reduced
effectiveness of the rifampicin/clarithromycin regimenhorized reproduction of this article is prohibited.
nt of Infectious Diseases, Geelong Hospital, Geelong,
ne Hospital, University of Melbourne, Melbourne, Australia,
Center for Infectious Diseases Epidemiology Research,
ent of HIV, University Hospitals of Geneva, Geneva,
ment of Infectious Diseases, Geelong Hospital, Geelong,
en@amsterdam.msf.org
pril 2013.
lth | Lippincott Williams & Wilkins 2177
Co
2178 AIDS 2013, Vol 27 No 14for Buruli ulcer treatment with secondary treatment
failure and drug resistance. Increased toxicity is also
reported when the two drugs are combined with 46%
of patients reported to develop a rash [15]. Finally,
clarithromycin is given twice daily making adherence
more difficult.
An alternative is moxifloxacin, which is more active
against Mycobacterium ulcerans than clarithromycin in vitro
[16], and in the mouse model shows equivalent efficacy in
combination with rifampicin as both rifampicin/strep-
tomycin and rifampicin/clarithromycin combinations
[11]. Clinical experience in observational studies has
shown it to be effective in combination with rifampicin
for curing lesions and preventing recurrences [7,17].
It has high oral bioavailability, excellent bone and tissue
penetration to reach the areas where the organism is active
[18,19], and has the advantage of being administered
only once daily. Although rifampicin is reported to
reduce moxifloxacin serum levels by 25–30% [20], the
maximal serum concentration after an oral 400mg
dose (3.2–4.5mg/ml) [21] remains in excess of its
reported minimal inhibitory concentration forM. ulcerans
(0.5mg/ml) [16], and should not reduce its effectiveness,
as evidenced by its successful use combined with
rifampicin treating M. ulcerans [7,17] and in human TB
trials [22,23]. Finally, it does not interact with
antiretroviral drugs. Therefore, it could potentially be
effectively combined with rifampicin for treatment of
Buruli ulcer/HIV-infected patients receiving ARTwhile
offering a number of advantages over the combination
of rifampicin/clarithromycin. It will be important to
perform further research to confirm the safety of
rifampicin/moxifloxacin combinations for Buruli ulcer/
HIV treatment, although it has been found that
when moxifloxacin is added to TB regimens containing
rifampicin, toxicity has not been increased [22,23].
Buruli ulcer/HIV-infected patients also live in areas
highly endemic for TB and are likely to have high rates
of TB infection. Buruli ulcer/HIV-infected patients,
especially if significantly immunosuppressed, are there-
fore also likely to have an increased risk of developing
active TB. If moxifloxacin were used in Buruli ulcer
treatment regimens, a concern could be that if used in
patients with active TB the organism could develop
resistance against it and this would remove an important
drug in current drug-resistant TB treatment regimens.
Yet, this potential disadvantage in HIV populations is
perhaps its greatest strength. First, moxifloxacin is active
against dormant TB in vitro, and its activity is increased
when combined with rifampicin [24]. It also has strong
early bactericidal activity against active TB in vivo [25].
When combined with rifampicin for an 8-week Buruli
ulcer treatment course, it may provide effective treatment
of latent TB [24], as has been demonstrated with 2-month
courses of rifampicin and pyrazinamide [26]. This would
offer a significant advantage, as TB is the greatest killer ofpyright © Lippincott Williams & Wilkins. UnauthoHIV-infected patients, and to try and minimize this,
treatment for latent TB is strongly recommended for all
HIV-infected patients [27]. Secondly, although of course
it would be important to exclude active TB prior
to commencement of, and during treatment with,
moxifloxacin-based regimens [27], if active TB disease
were present but undetected, then moxifloxacin would
likely reduce the likelihood of rifampicin resistance
developing during an 8-week treatment course [28], and
thus help prevent the development of rifampicin-resistant
TB. It would also be more likely to prevent rifampicin-
resistant TB than the alternative agents given high rates
of streptomycin TB resistance globally and the limited
activity of clarithromycin against TB. Additionally,
current experience suggests that the number of
Buruli ulcer/HIV patients with active TB is low further
minimizing the public health risk.
So, for HIV-infected patients with Buruli ulcer living in
high-burden TB regions moxifloxacin has the potential
to effectively and safely relieve the significant burden of
Buruli ulcer disease while allowing the use of once-
daily all oral antibiotic regimens that will aid adherence,
reduce toxicity, and facilitate treatment availability in
decentralized community settings. Additionally, it may
kill two birds with one stone by potentially also providing
life-saving eradication of TB infection or reducing
the development of rifampicin-resistant TB disease.
Therefore, we advocate for research to be urgently
undertaken into the use of moxifloxacin combined with
rifampicin to determine its effectiveness and safety as
treatment for Buruli ulcer in HIV-infected adults on
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